Agreed, not exactly something to be proud about regarding the early 2000 gain which some apparently did not take advantage of. Especially as there was no substance to the valuation then as there appears to be now. Back to my question, as I value your opinion and respect your right not to answer, what other biotechs out there do you consider good buys at this point?
News 
Market Data 
Discover 
AI
